In addition, the Drp-1 inhibitor administrated before the onset of cerebral ischemia may have beneficial effects in the case of cerebrovascular diseases, including carotid occlusive disease, and moyamoya disease to prevent cerebral ischemia in the future. Here, DNM1L is linked to Moyamoya disease.